All In Biotech

Free tool

Drugs in development

Investigational drugs and biologics in industry-sponsored Phase 2 and Phase 3 trials that are active or finished in the last two years, and that FDA has not approved. Built from 10,322 ClinicalTrials.gov records, with code names and generic names merged. For approved drugs, use Drug Search.

Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations

Drugs in development

3,685

Not FDA-approved

In Phase 3

1,424

Highest phase reached

Matching your filters

3

Reset

3 drugs in development

Names, sponsors and conditions come from the trial records. Click a drug for its trials.

  • ALXN2220Phase 34 trials

    AstraZeneca · Transthyretin Amyloid Cardiomyopathy (ATTR-CM), Transthyretin Amyloid Cardiomyopathy, Amyloid Transthyretin Cardiomyopathy

  • NNC6019-0001Phase 33 trials

    Novo Nordisk · Transthyretin Amyloid Cardiomyopathy (ATTR CM)

  • NucresiranALN-TTRSC04Phase 32 trials

    Alnylam Pharmaceuticals · Transthyretin Amyloidosis With Cardiomyopathy, Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, hATTR-PN

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.